BridgeBio Pharma (BBIO) Interest Expenses (2018 - 2026)
BridgeBio Pharma (BBIO) posted Interest Expenses of $20.3 million for Q1 2026, up 115.37% sequentially from $9.4 million in Q4 2025, and down 12.7% YoY from $23.3 million in Q1 2025.
BridgeBio Pharma (BBIO) Interest Expenses (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Interest Expenses for 9 years, with the latest figure at $20.3 million in Q1 2026.
- Quarterly Interest Expenses fell 12.7% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.1 million (down 30.21% YoY) and the FY2025 annual result came in at $968.0 million, up 33.09% from the prior year.
- Interest Expenses rose to $20.3 million in Q1 2026 per BBIO's latest filing, from $9.4 million in the prior quarter.
- Over five years, Interest Expenses peaked at $205.3 million in Q2 2025 and troughed at $9.4 million in Q4 2025.
- A 5-year average of $37.2 million and a median of $20.6 million in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2024: Interest Expenses tumbled 80.79% in 2022, then jumped 221.02% in 2024.
- Over 5 years, Interest Expenses stood at $20.0 million in 2022, then soared by 52.39% to $30.5 million in 2023, then sank by 56.98% to $13.1 million in 2024, then slipped by 28.03% to $9.4 million in 2025, then surged by 115.37% to $20.3 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $20.3 million, $9.4 million, and $62.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | 48.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.87 Mn |
| Jun 30, 2026 | 48.87 Mn |
| Mar 31, 2026 | 20.32 Mn |
| Mar 31, 2026 | 20.32 Mn |
| Dec 31, 2025 | 9.43 Mn |
| Dec 31, 2025 | 9.43 Mn |
| Sep 30, 2025 | 61.96 Mn |
| Sep 30, 2025 | 61.96 Mn |
| Jun 30, 2025 | 205.28 Mn |
| Jun 30, 2025 | 205.28 Mn |
| Mar 31, 2025 | 23.27 Mn |
| Mar 31, 2025 | 23.27 Mn |
| Dec 31, 2024 | 13.11 Mn |
| Dec 31, 2024 | 13.11 Mn |
| Sep 30, 2024 | 23.06 Mn |
| Sep 30, 2024 | 23.06 Mn |
| Jun 30, 2024 | 66.11 Mn |
| Jun 30, 2024 | 66.11 Mn |
| Mar 31, 2024 | 35.32 Mn |
| Mar 31, 2024 | 35.32 Mn |